Recent News

• 03.25.2026 - Denali Therapeutics Announces U.S. FDA Approval of AVLAYAH™ (tividenofusp alfa-eknm) for Treatment of Hunter Syndrome (MPS II)
• 02.26.2026 - Denali Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
• 02.05.2026 - Denali Therapeutics Presents Enzyme TransportVehicle™ Progress Across Three Clinical Programs for Treatment of Lysosomal Storage Disorders at 2026 WORLDSymposium™
• 02.02.2026 - Denali Therapeutics To Host Webcast Highlighting Presentations on Enzyme TransportVehicle™ Programs at the 2026 WORLDSymposium™
• 01.29.2026 - Denali Therapeutics Announces Data Presentations on Enzyme TransportVehicle™ Programs for Hunter Syndrome, Sanfilippo Syndrome Type A and Pompe Disease at Upcoming 2026 WORLDSymposium™
• 01.06.2026 - Denali Therapeutics Announces Key Anticipated Milestones and Priorities for 2026 Including Commercial Launch of Tividenofusp Alfa for Hunter Syndrome

Recent Filings

• 03.26.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 03.25.2026 - 8-K Current report
• 03.25.2026 - EX-99.1 EX-99.1
• 02.26.2026 - 8-K Current report
• 02.26.2026 - EX-99.1 EX-99.1
• 02.26.2026 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 02.26.2026 - S-8 Securities to be offered to employees in employee benefit plans
• 02.05.2026 - 144 Report of proposed sale of securities
• 02.04.2026 - 144 Report of proposed sale of securities
• 02.03.2026 - 144 Report of proposed sale of securities